Targeting the next viral threat.
PROGENITER is creating a suite of ready-to-deploy antibody treatments to ensure that Canada is ready to respond quickly to the next novel pathogen.
Proactive research, development, and deployment
PROGENITER
Pathogen Response Optimization by GENeratIng ThErapeutics Rationally
PROGENITER is a research and infrastructure program that seeks to build a regional platform to quickly design, test, and manufacture biologics to support research and early therapeutic development for emerging infectious diseases. It is a strategic and forward-looking effort focused on boosting biomanufacturing resilience and rapid biomedical response.
The sense of urgency that pandemics generate must nevertheless not be relegated to times of crisis. PROGENITER is a nationally recognized, multi-year research program that aims to discover, design, produce, characterize and deliver new treatments that target current and future infectious disease threats.
PROGENITER is a multidisplinary academic-industry partnership that will bolster Canada’s pandemic preparedness by creating a suite of ready-to-deploy antibody treatments for current health threats like COVID-19 and influenza, and position Canadian researchers and healthcare systems to respond rapidly to novel threats as they emerge.